BD Q4 profit hurt by safety syringe court battle
This article was originally published in Clinica
Executive Summary
Becton Dickinson experienced a “core revenue growth bonanza” during its fourth fiscal quarter according to Jefferies analyst Brandon Couillard – but this did not stop its bottom line from shrinking as it absorbed charges from a legal battle with Retractable Technologies (RTI).